Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
HQY Stock Forecast 2026-2027
$84.84
Current Price
$7.17B
Market Cap
Buy 14
Hold 0
Sell 1
Wall St Analyst Ratings
Distance to HQY Price Targets
+50.9%
To High Target of $128.00
+29.7%
To Median Target of $110.00
+1.4%
To Low Target of $86.00
HQY Price Momentum
+3.0%
1 Week Change
+0.8%
1 Month Change
-6.2%
1 Year Change
-7.4%
Year-to-Date Change
-27.3%
From 52W High of $116.65
+16.6%
From 52W Low of $72.76
📊 TOP ANALYST CALLS
Did HQY Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if HealthEquity is one of their latest high-conviction picks.
Latest HQY Stock Price Targets & Analyst Predictions
Based on our analysis of 27 Wall Street analysts, HQY has a bullish consensus with a median price target of $110.00 (ranging from $86.00 to $128.00). The overall analyst rating is Strong Buy (8.8/10). Currently trading at $84.84, the median forecast implies a 29.7% upside. This outlook is supported by 14 Buy, 0 Hold, and 1 Sell ratings.
The most optimistic forecast comes from George Hill at Deutsche Bank, projecting a 50.9% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
HQY Analyst Ratings
14
Buy
0
Hold
1
Sell
HQY Price Target Range
Low
$86.00
Average
$110.00
High
$128.00
Current: $84.84
Latest HQY Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for HQY.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Apr 9, 2026 | BMO Capital | Sean Dodge | Outperform | Upgrade | $105.00 |
| Mar 19, 2026 | Deutsche Bank | George Hill | Buy | Maintains | $128.00 |
| Mar 18, 2026 | JP Morgan | Alexei Gogolev | Overweight | Maintains | $123.00 |
| Mar 18, 2026 | Barrington Research | Alexander Paris | Outperform | Maintains | $110.00 |
| Mar 18, 2026 | RBC Capital | Daniel R. Perlin | Outperform | Maintains | $100.00 |
| Feb 18, 2026 | Barclays | Glen Santangelo | Overweight | Maintains | $110.00 |
| Feb 17, 2026 | BTIG | David Larsen | Buy | Maintains | $110.00 |
| Jan 9, 2026 | Goldman Sachs | David Roman | Sell | Downgrade | $89.00 |
| Jan 8, 2026 | Keybanc | Scott Schoenhaus | Overweight | Maintains | $125.00 |
| Dec 9, 2025 | Barclays | Glen Santangelo | Overweight | Initiates | $118.00 |
| Dec 4, 2025 | JP Morgan | Alexei Gogolev | Overweight | Maintains | $129.00 |
| Dec 4, 2025 | Barrington Research | Alexander Paris | Outperform | Maintains | $125.00 |
| Dec 4, 2025 | BTIG | David Larsen | Buy | Reiterates | $130.00 |
| Dec 4, 2025 | Citizens | Constantine Davides | Market Outperform | Maintains | $122.00 |
| Nov 13, 2025 | BMO Capital | Sean Dodge | Market Perform | Initiates | $100.00 |
| Oct 8, 2025 | Keybanc | Scott Schoenhaus | Overweight | Maintains | $120.00 |
| Sep 3, 2025 | Jefferies | Glen Santangelo | Buy | Maintains | $134.00 |
| Sep 3, 2025 | JP Morgan | Anne Samuel | Overweight | Maintains | $126.00 |
| Sep 3, 2025 | RBC Capital | Daniel R. Perlin | Outperform | Maintains | $110.00 |
| Sep 3, 2025 | Barrington Research | Alexander Paris | Outperform | Maintains | $125.00 |
HealthEquity Inc (HQY) Competitors
The following stocks are similar to HealthEquity based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
HQY
HealthEquity
mkt cap
6.96B
HealthEquity Inc (HQY) Financial Data
HealthEquity Inc has a market capitalization of $7.17B with a P/E ratio of 34.1x. The company generates $1.31B in trailing twelve-month revenue with a 16.4% profit margin.
Revenue growth is +7.3% quarter-over-quarter, while maintaining an operating margin of +21.6% and return on equity of +10.2%.
Valuation Metrics
Market Cap
$7.17B
Enterprise Value
$7.78B
P/E Ratio
34.1x
PEG Ratio
0.4x
Price/Sales
5.4x
Growth & Margins
Revenue Growth (YoY)
+7.3%
Gross Margin
+68.2%
Operating Margin
+21.6%
Net Margin
+16.4%
EPS Growth
+88.7%
Financial Health
Cash/Price Ratio
+4.4%
Current Ratio
3.3x
Debt/Equity
47.5x
ROE
+10.2%
ROA
+6.0%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
HealthEquity Inc (HQY) Business Model
About HealthEquity Inc
What They Do
Provides technology services for healthcare savings management.
Business Model
HealthEquity Inc. operates a technology-enabled services platform that manages health savings accounts (HSAs), flexible spending accounts (FSAs), and health reimbursement arrangements (HRAs). The company generates revenue by administering these accounts, offering investment platforms, payment processing, and advisory services, thereby facilitating efficient healthcare expense management for consumers and employers.
Additional Information
Founded in 2002 and based in Draper, Utah, HealthEquity Inc. is a recognized non-bank HSA trustee designated by the IRS. The company also provides COBRA continuation services and personalized benefit information, contributing to its role in the growing consumer-driven healthcare market.
Company Information
Sector
Healthcare
Industry
Health Information Services
Employees
2,814
CEO
Mr. Scott R. Cutler J.D.
Country
United States
IPO Year
2014
Website
www.healthequity.comHealthEquity Inc (HQY) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
Concentra Group (CON) Q1 Earnings and Revenues Beat Estimates
Concentra (CON) delivered earnings and revenue surprises of +14.29% and +2.76%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
May 07, 2026
By Zacks Equity Research
Tale of the Tape
Ardent Health, Inc. (ARDT) Surpasses Q1 Earnings and Revenue Estimates
Ardent Health, Inc. (ARDT) delivered earnings and revenue surprises of +53.43% and +1.34%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
May 06, 2026
By Zacks Equity Research
Tale of the Tape
Latest News
HealthEquity Announces First Quarter Earnings Release Date and Investor Conference Schedule
4 days ago
Quick Summary
HealthEquity, Inc. (NASDAQ: HQY) will release its Q1 fiscal 2027 financial results on May 28, 2026, after market close, followed by a conference call at 4:30 p.m. the same day.
Why It Matters
HealthEquity's upcoming financial results and conference call could influence stock performance and investor sentiment, providing insights into the company's growth and market position.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Zacks Style Scores helps investors identify top-rated stocks tailored to their investing style, providing a useful tool for stock selection.
Why It Matters
The Zacks Style Scores can help investors identify high-potential stocks aligned with their investment strategies, potentially enhancing portfolio performance and decision-making efficiency.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Investors in the Medical Services sector are considering Solventum (SOLV) and HealthEquity (HQY) for potential value investments.
Why It Matters
The comparison between Solventum and HealthEquity highlights potential investment opportunities in the Medical Services sector, indicating differing valuations that could impact returns.
Source: Zacks Investment Research
Market Sentiment:
Neutral
Quick Summary
Zacks Premium offers Style Scores to help investors identify strong stocks across value, growth, or momentum strategies.
Why It Matters
Zacks Style Scores enhance stock selection across investment strategies, potentially improving returns and reducing risk by identifying strong candidates for various investor profiles.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
HealthEquity (HQY) recently reported earnings. Investors should monitor upcoming developments and performance trends for potential stock movements.
Why It Matters
HealthEquity's recent earnings report can signal its financial health and future growth potential, influencing investor sentiment and stock performance.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Zacks Premium research service offers Zacks Style Scores, aiding value, growth, and momentum investors in identifying strong stocks.
Why It Matters
The Zacks Style Scores can enhance stock-picking strategies across various investment styles, potentially leading to better returns and informed decision-making.
Source: Zacks Investment Research
Market Sentiment:
Positive
Frequently Asked Questions About HQY Stock
What is HealthEquity Inc's (HQY) stock forecast for 2026?
Based on our analysis of 27 Wall Street analysts, HealthEquity Inc (HQY) has a median price target of $110.00. The highest price target is $128.00 and the lowest is $86.00.
Is HQY stock a good investment in 2026?
According to current analyst ratings, HQY has 14 Buy ratings, 0 Hold ratings, and 1 Sell ratings. The stock is currently trading at $84.84. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for HQY stock?
Wall Street analysts predict HQY stock could reach $110.00 in the next 12 months. This represents a 29.7% increase from the current price of $84.84. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is HealthEquity Inc's business model?
HealthEquity Inc. operates a technology-enabled services platform that manages health savings accounts (HSAs), flexible spending accounts (FSAs), and health reimbursement arrangements (HRAs). The company generates revenue by administering these accounts, offering investment platforms, payment processing, and advisory services, thereby facilitating efficient healthcare expense management for consumers and employers.
What is the highest forecasted price for HQY HealthEquity Inc?
The highest price target for HQY is $128.00 from George Hill at Deutsche Bank, which represents a 50.9% increase from the current price of $84.84.
What is the lowest forecasted price for HQY HealthEquity Inc?
Price targets from Wall Street analysts for HQY are not currently available. The stock is trading at $84.84.
What is the overall HQY consensus from analysts for HealthEquity Inc?
The overall analyst consensus for HQY is bullish. Out of 27 Wall Street analysts, 14 rate it as Buy, 0 as Hold, and 1 as Sell, with a median price target of $110.00.
How accurate are HQY stock price projections?
Stock price projections, including those for HealthEquity Inc, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: May 9, 2026 8:21 AM UTC